Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Sinonasal Tumors are a rare type of head and neck tumor, accounting for approximately 3% of head and neck cancers. Treatment primarily involves surgical intervention, with radiation therapy as an adjunct. Due to the tumor's anatomical location near critical structures such as the eyes, optic nerves, optic chiasm, brainstem, and oral cavity, if the tumor cannot be completely resected, postoperative radiation therapy is often necessary. Given the complexity of the tumor's anatomical position, subsequent radiation therapy planning becomes more challenging, as it must balance tumor control and organ preservation. This study retrospectively analyzes patients with sinonasal tumors who received stereotactic radiosurgery (CyberKnife) at our hospital, comparing the dosimetric advantages, treatment efficacy, survival analysis, and side effects with those of volumetric modulated arc therapy (VMAT).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sinonasal malignancy patients received post-operative cyberknife | Sinonasal malignancy patients in our hospital receive curative surgery. These patients received post-operative radiotheray of SBRT by cyberknife. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SBRT by Cyberknife | Radiation | The patients with sinonasal maliganacy receive curative surgery then receive adjuvant RT by the method of SBRT by Cyberknife. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival, OS | Determine the start dates of surgery and radiotherapy from the hospital's medical record system, and collect data on death events, regardless of whether they are tumor-related. | Data within five years after treatment. |
| Disease-Free Survival, DFS | Determine the treatment start date from the hospital's medical record system, and confirm whether there is any disease recurrence or progression through follow-up data or imaging examination results. | Data within five years after treatment |
| Local Control, LC | Measure the proportion of no recurrence in the local tumor area after treatment. Researchers determine the treatment start date from the hospital's medical record system and confirm the presence or absence of local tumor recurrence through follow-up data, imaging examinations, and pathology results. | The observation periods are 1 year, 3 years, and 5 years after treatment. |
| Distant Metastasis-Free Survival, DMFS | Measure the time until the occurrence of distant metastasis after treatment. Researchers first determine the treatment start date, and then assess distant metastasis through data, imaging examinations, and clinical evaluations. | The observation periods are 1 year, 3 years,and 5 years after treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| treatment-related side effects | Acute or chronic side effects caused by treatment can include radiation dermatitis, dry mouth, vision impairment, and so on. | complications related to treatment within 30 days |
| Dosimetric Outcomes |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The sixth-generation computer-assisted radiotherapy system was introduced at this hospital in 2019. This study will attempt to analyze the dose differences between treatment plans using traditional linear accelerators and those using the computer-assisted system for patients who received stereotactic radiotherapy at this hospital over the past five years.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Taichung Veterans General Hospital | Taichung | Taiwan |
Not provided
| ID | Term |
|---|---|
| D006258 | Head and Neck Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
The quality of a radiation therapy plan can be assessed through dose uniformity and dose constraints for adjacent critical organs (such as the optic nerve and brainstem). Researchers first collect dose distribution data from the treatment planning system and use dose calculation software to analyze dose uniformity indices (such as the homogeneity index) to evaluate the distribution of doses. At the same time, dose constraint standards for adjacent critical organs are established to ensure that the doses to these organs remain within safe limits during treatment. These indicators reflect the quality of the radiation therapy plan and can help researchers assess the safety and efficacy of the treatment.
| Data for five years after treatment. |